摘要
目的探讨套细胞淋巴瘤的临床特征和免疫表型特点。方法回顾性分析23例套细胞淋巴瘤患者的临床资料。对患者的年龄、性别、临床分期、淋巴结及结外病变、骨髓活检、血清乳酸脱氢酶和免疫表型等进行分析。结果患者中位年龄62岁（44～74岁），≥60岁者15例（65．2％）。男女比例为4．8：1。Ann Arbor临床分期Ⅲ期12例，Ⅳ期9例。首发症状为浅表淋巴结肿大20例（87．0％），以颈部最多；伴有腹腔内淋巴结肿大13例（56．5％）。病程早期发热者9例（39．1％），15例行骨髓穿刺患者中骨髓有肿瘤细胞浸润10例（66．6％）。血清乳酸脱氢酶增高11例（47．8％）。免疫表型CD，阳性14例（60．9％），CD20阳性21例（913％）。Cyclin D1过度表达19例（82．6％）。结论套细胞淋巴瘤主要发生在男性老年人群，初诊时多为晚期，多有骨髓浸润。首发症状为浅表淋巴结肿大，结外病变明显。免疫表型检测显示套细胞淋巴瘤有成熟B细胞（CD20＋）抗原，同时兼有T细胞（CD5＋）的抗原。免疫组织化学呈现CvclinD1讨席表弑可为诊断套细朐淋巴瘤的余标准．
Objective To investigation the clinical features and immunophenotypes of mantle cell lymphoma （MCL）. Methods The clinical data of 23 patients of MCL were reviewed prospectively. Age, sex, Ann-Arbor staging, symptoms and bone marrow biopsies were analyzed. Serum lactat dehydrogenates （LDH） level, CD5, CD20 and CyclinDl were determined. Results The median age was 62 years old （range 44-74）, 15 patients （65.2%） were more than 60 years old. Among 23 patients, the male-to-female ratio was 4.4：1. Twenty-one patients （91%） presented with advanced stage （Ann Arbor stage III 12 cases and IV 9 cases） at initial diagnosis. Twenty patients （87.0 %） were lymph node involvement. The serum LDH level was high in 11 patients. CD5 was positively expressed in 14 （60.8 %） of all patients. CD20 was positively expressed in 21 （91.3 %） of all patients. Cyclin D1 was over-expression in 19 （82.6 %） of all patients. Conclusion The MCL shows a predilection for occurrence in older males. The majority of patients are advanced stage disease （Ann Arbor stage III/IV ） are at initial diagnosis. Most of patients display lymph node involvement manifestations. Bone marrow infiltration is frequent. The immunophenotype of MCL resembles the mature B-lymphocyte （CD20＋）, with coexprssion of the T-cell antigen CD5＋. It has been demonstrated that CyclinD1 are over express in this histotype of MCL. CyclinD1 over-expression could be considered as hallmark of MCL.
出处
《白血病．淋巴瘤》
CAS
2011年第10期606-607,共2页
Journal of Leukemia & Lymphoma
关键词
淋巴瘤
膜细胞
临床特征
免疫表型分型
Lymphoma, mantle-cell
Clinical feature
Immunophenotyping
